FDA approves Arcutis Biotherapeutics’ ZORYVE for pediatric and adult atopic dermatitis

In a significant development for the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the U.S. Food and Drug Administration (FDA) approval ... Read More